Vaxcyte, INC Schedule 13G passive stakes

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Vaxcyte, Inc., reporting a 12.1% stake.

Janus Henderson Group Ltd. has filed an amendment to its Schedule 13G, reporting a decrease in its beneficial ownership of Vaxcyte, Inc. common stock.

RA Capital Management and its principals have reported an 8.9% beneficial ownership stake in Vaxcyte, Inc. as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 16,575,875 shares, representing 11.5% of Vaxcyte, Inc.'s common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 11.4% of Vaxcyte Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.03% of Vaxcyte Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Vaxcyte Inc. following an internal corporate realignment.

T. Rowe Price Investment Management, Inc. has reported a 6.4% beneficial ownership stake in VAXCYTE INC, holding over 8.3 million shares of common stock.

Janus Henderson Group plc has reported an increased beneficial ownership in Vaxcyte, Inc. common stock, now holding 10.1% of the class as of September 30, 2025.

FMR LLC and Abigail P. Johnson have reported a 10.1% beneficial ownership stake in Vaxcyte Inc. common stock.

Janus Henderson Group plc has increased its passive ownership in Vaxcyte, Inc. to 11.4% of common stock, holding over 14.69 million shares.

FMR LLC and Abigail P. Johnson have disclosed a beneficial ownership of 9.4% in VAXCYTE INC common stock as of June 30, 2025.

RA Capital Management, along with its principals and affiliated funds, has filed an amended Schedule 13G/A, disclosing a 9.9% beneficial ownership stake in Vaxcyte, Inc. as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a beneficial ownership of 11.3% in Vaxcyte, Inc.'s common stock as of April 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its beneficial ownership of 7.6% of VAXCYTE, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 8.5% of Vaxcyte Inc.'s common stock as of December 31, 2024.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, confirming a 10.5% beneficial ownership stake in VAXCYTE INC as of December 31, 2024.